Ann: Dispute with Solagran Limited , page-31

This might suit both parties? Relative parity in the SP could lead to a trade off in cross holdings to square that issue away too? Bioeffectives are only one product path for BPO - I'll wait to see Solagran's response before reading too much into the JV situation, but looks positive for BPO in any case. I'd like to see what other CGNC products in both animal and human health areas the ann. refers too [doubt we would see too much detail until dispute resolution or termination].